Remove 2023 Remove Individual Remove Screening Remove Transportation
article thumbnail

Social Risk Burden and Its Impact on Healthcare Use in IBD

Physician's Weekly

High social risk burden in adults with IBD drives emergency care use and medication gaps—spotlighting the urgent need for social screening in clinical practice. Social risk burden was categorized as none (0/6 domains), mild (1/6), moderate (2/6), and severe (≥3/6).

article thumbnail

Episode 322: Antiracism in Medicine – Episode 24 – Leveraging Narrative Medicine to Cultivate Antiracist Praxis

The Clinical Problem Solvers

She discovered narrative medicine, and to her, it was about finding and retelling individual and structural stories in antiracist ways. Listening to individual stories within the context of their structural stories is important. Listening to individual stories within the context of their structural stories is important.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Caring for the Unrepresented: A Podcast with Joe Dixon, Timothy Farrell, Yael Zweig

GeriPal

These individuals may become unrepresented, meaning they lack the capacity to make a specific medical decision, do not have an advance directive for that decision, and do not have a surrogate to help. How should we care for unrepresented individuals in inpatient and outpatient settings? It’s been revised in 2023.

article thumbnail

Sweet! A Metabolic Disorders focused podcast episode

PEMBlog

She aims to become a physician-scientist in pediatrics and medical genetics, engaging in bench-to-bedside research that utilizes multi-omics-based approaches to provide a molecular diagnosis and support personalized care for individuals with suspected rare genetic diseases and their families. Updated 2023 Jul 17].

article thumbnail

Better Late Than Never – Unpacking FDA’s Highly Anticipated (and Long Overdue) Draft Guidance on Diversity Action Plans

FDA Law Blog

The deadline for the Draft Guidance was December 29, 2023, so the draft, issued on June 26, 2024, is about 6 months late under FDORA’s mandate. We’ve blogged about some of FDA’s efforts to increase diversity in clinical trials previously, and the Draft Guidance itself describes a variety of these efforts.

Clinic 59
article thumbnail

Guiding an Improved Dementia Experience (GUIDE) Model: A Podcast with Malaz Boustani and Diane Ty

GeriPal

So I thought… And I was doing this for the United States Preventive Services Task Force because we were looking at the evidence to what’s the benefit and harm of screening, and I had to look all over. So we came out with a report in March of 2023, followed it on the heels of a report that we had done in November, 2022.